CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Last Updated: Tuesday, May 13, 2025

Researchers investigated the combined targeting of CD70 and CD33 to overcome acute myeloid leukemia antigen heterogeneity. They found that CD70-targeted CAR T cells secreting a CD33 T-cell–engaging antibody molecule showed feasibility in overcoming AML heterogeneity and leveraging patients’ bystander T cells.

Blood

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

International Immunopharmacology

The paths toward immunotherapy of esophageal cancer: An overview of clinical trials

Trends in Pharmacological Sciences

Boosting CAR-T cell therapy through vaccine synergy

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

CAR T-Cell Therapy Resource Center

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

International Immunopharmacology

The paths toward immunotherapy of esophageal cancer: An overview of clinical trials

Trends in Pharmacological Sciences

Boosting CAR-T cell therapy through vaccine synergy

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets